Insider Trading (Form 4)
NASDAQ
Eran Rotem, Deputy CEO and CFO of CollPlant Biotechnologies Ltd, received 510,372 shares of common stock on September 3, 2026.
NASDAQ
Bar Berta Abelis, VP Legal of CollPlant Biotechnologies Ltd, received 201,141 shares of common stock on September 3, 2026.
Schedule 13D - Activist Investments
See all →NASDAQ
The Loewenbaum Group has filed an amendment to its Schedule 13D, reporting a collective beneficial ownership of 24.99% in CollPlant Biotechnologies Ltd. ordinary shares and warrants.
NASDAQ
The Loewenbaum Group has disclosed an increased beneficial ownership in CollPlant Biotechnologies, acquiring significant shares and warrants through a securities purchase agreement.
NASDAQ
The Loewenbaum Group has amended its Schedule 13D filing, disclosing a significant investment in CollPlant Biotechnologies Ltd. through a recent securities purchase agreement.
NASDAQ
SCHEDULE 13D/A: Insider Sells Collplant Shares, Ownership Drops to 12.9%
Ami Sagy, a significant beneficial owner, has reduced his stake in Collplant Biotechnologies Ltd. by selling 140,000 ordinary shares, bringing his total ownership to 12.9%.
Worse than expected
NASDAQ
A group of significant shareholders, including George Walter Loewenbaum, has withdrawn its request to nominate Nachum Homi Shamir to CollPlant Biotechnologies' Board of Directors.
NASDAQ
A group of investors, holding 15.8% of CollPlant Biotechnologies, is advocating for immediate changes to the company's Board of Directors, including a new Chairman.
Capital raise
Worse than expected
Schedule 13G - Passive Investments
NASDAQ
George Walter Loewenbaum and affiliated entities have filed an amended Schedule 13G/A, disclosing a combined passive beneficial ownership in CollPlant Biotechnologies Ltd., with George Walter Loewenbaum holding 9.96% of the ordinary shares.